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The pathogenetic mechanisms involved in the development of
sporadic idiopathic hypoparathyroidism are currently under
investigation. Although autoantibodies against the calcium-
sensing receptor (CaSR) have been implicated to play a role,
these could be demonstrated in only 49% of a group of 51
patients with sporadic idiopathic hypoparathyroidism that
we previously studied. Therefore, we investigated 49 of these
patients further, regardless of their antibody status, and
looked for mutations in the section of the PTH gene sequence
that coded for prepro-PTH as well as the 3-untranslated re-
gion (3-UTR) of the gene, which is believed to be involved in
the stability of its mRNA. We also examined the relationship
between the clinical manifestations of the disease and the
occurrences of two commonly observed single nucleotide
polymorphisms (SNPs) in the PTH gene. In 49 of the patients
with idiopathic hypoparathyroidism and in 55 healthy con-
trols, the SNPs were characterized by restriction analysis us-
ing DraII and BstBI enzymes. In a subset of these patients,
exons 2 and 3 of the PTH gene (n  37) and its 3-UTR region
(n  40) were also sequenced. No mutations were observed in
the segment of the PTH gene coding for the signal peptide,
prohormone, or the 3-UTR region. However, three well de-
scribed SNPs were observed: 1) an A3G substitution in intron
1 in 35.1% of the patients; 2) a G3A substitution in intron 2,
characterized by BstBI, in one or both alleles in 27%; and 3) a
C3A substitution at codon 52 (CGA) of exon 3, characterized
by DraII, in one or both alleles in 59.7% of the patients. There
was no significant difference in the frequency of occurrence
of these SNPs between the patient and the control groups.
Furthermore, the mean age at onset of symptoms, body mass
index, frequency of cataract, tetany, convulsion, basal ganglia
calcification, serum calcium, inorganic phosphorus, and in-
tact PTH were not significantly different between patients
with and without the above-described SNPs. Thus, the data
from this report demonstrate that in patients with sporadic
idiopathic hypoparathyroidism, neither the clinical manifes-
tations nor the biochemical indexes of the disease are related
to the occurrence of mutations or SNPs in the PTH gene.
Because neither patient nor control samples exhibited any
variations in the sequence of their 3-UTR regions, it is un-
likely that mRNA instability is a factor in the pathogenesis of
the disease. Additional studies are required to investigate the
role of other genes and autoantigens that may be involved in
the genesis of idiopathic hypoparathyroidism. (J Clin Endo-
crinol Metab 89: 4840–4845, 2004)
THE FUNDAMENTAL MECHANISMS involved in thedevelopment of idiopathic hypoparathyroidism still
remain unidentified and are currently a subject of investi-
gation. We recently demonstrated autoantibodies against the
calcium-sensing receptor (CaSR) in 49% of a group of 51
patients with idiopathic hypoparathyroidism (1). The pres-
ence of CaSR autoantibodies in association with specific hu-
man leukocyte antigen DR haplotypes indicate organ-
specific autoimmunity; therefore, this subset of patients
could be classified as having autoimmune hypoparathyroid-
ism. However, the remaining half of the patients in whom no
CaSR autoantibodies could be detected would still have to be
classified as having idiopathic hypoparathyroidism. Studies
in patients with familial hypoparathyroidism have revealed
point mutations in the signal peptide-coding region of PTH
gene in some of them (2, 3). The human PTH gene has been
cloned; it is located on chromosome 11 and consists of three
exons. Exon 1 is untranslated, exon 2 codes for the 25-amino
acid signal peptide and part of the prohormone, and exon 3
codes for the remaining part of the prohormone (six amino
acids) and the whole PTH molecule (84 amino acids; Fig. 1).
In humans, the terminal region of exon 3 consisting of 351
nucleotides remains untranslated [3-untranslated region
(3-UTR)] (4, 5). In rats, the distal terminal portion of this UTR
is related to the stability of PTH mRNA (6) and contains
a 26-nucleotide-long cis-acting element (TATTGTTTAT-
TCTTTTTAAAGTATGT) that binds a parathyroid cytosolic
protein and is conserved among species, including humans.
In the familial form of hypoparathyroidism, mutations have
also been reported at a donor splice site in the intron 1-exon
2 junction (7). Suprasdngsin et al. (8) described a point mu-
tation in the signal peptide-encoding region of the PTH gene
in an isolated patient with the sporadic form of idiopathic
hypoparathyroidism. A mutation occurring in the region
coding for the signal peptide impairs the interaction of the
nascent protein with the signal recognition particle and the
translocation machinery (9). Three single nucleotide poly-
morphisms (SNPs) in the PTH gene sequence have been
observed frequently in both Caucasian as well as Asian pop-
ulations. These include an A3G substitution in intron 1, 10
nucleotides upstream of exon 2; a G3A substitution in in-
tron 2, 54 nucleotides downstream of the 3 end of exon 2; and
a C3A substitution in codon 52 (CGA) of exon 3. The last
Abbreviations: CaSR, Calcium-sensing receptor; iPTH, intact PTH;
SNP, single nucleotide polymorphism; 3-UTR, 3-untranslated region.
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two SNPs have been analyzed in detail by restriction frag-
ment length polymorphism studies using endonucleases
DraII and BstBI, and some of the different genotypes detected
in healthy populations have been found to be linked to the
presence of osteoporosis (10, 11). In patients with primary
hyperparathyroidism, Kanzawa et al. (12) reported a corre-
lation between PTH gene polymorphism and the severity of
the disease. Recently, Alvarez-Hernandez et al. (13) reported
coinheritance of mutations in exon 7 of both the CaSR gene
as well as the PTH gene SNPs in a family with autosomal
dominant hypoparathyroidism.
In the present study we investigated 49 patients with id-
iopathic hypoparathyroidism regardless of their antibody
status and looked for mutations in the section of the PTH
gene sequence that coded for prepro-PTH. The 3-UTR re-
gion was also sequenced, and the conserved stretch of 26
nucleotides concerned with the stability of PTH mRNA was
specifically examined for alterations. We also studied the
clinical manifestations of the disease as related to the occur-
rence of two commonly observed SNPs in the PTH gene.
Materials and Methods
The subjects in this study consisted of 49 patients (27 males and 22
females) with sporadic idiopathic hypoparathyroidism who attended
the endocrine clinic at the All India Institute of Medical Sciences (New
Delhi, India) from 1998–2003. The diagnosis of idiopathic hypopara-
thyroidism was based on the presence of hypocalcemia and hyperphos-
phatemia in association with subnormal or an inappropriately normal
level of serum intact PTH (iPTH). Their mean age at presentation was
32.1  13.8 yr (range, 10–59 yr), and the mean duration of their illness
was 6.8  7.7 yr (range, 1 d to 35 yr). Patients with postsurgical hypo-
parathyroidism were excluded. None of the patients had a family history
of hypoparathyroidism or any features, such as mucocutaneous candi-
diasis or autoimmune adrenal insufficiency, that could be suggestive of
hypoparathyroidism related to the polyglandular autoimmune type 1
syndrome/autoimmune polyendocrinopathy candidiasis ectodermal
dystrophy (14, 15). Autoimmune adrenal involvement was excluded by
demonstrating normal ACTH and serum cortisol values at 0800 h cou-
pled with no evidence of adrenal cortical autoantibodies on indirect
immunofluorescence (16). Computerized tomography to determine
basal ganglia calcification was carried out in all subjects, and cataract
was diagnosed by examination with a slit lamp. The clinical features of
the 49 patients included in this study are as follows. Both sexes showed
a similar predilection for the disease, and the male/female ratio was
1.2:1. The most common features observed included basal ganglia cal-
cification (76%), a history of generalized tonic clonic convulsions
(63.2%), and cataract (36.7%). The absence of any clinical or biochemical
evidence of adrenal insufficiency as well as mucocutaneus candidiasis
in all patients suggests that the polyglandular autoimmune type 1 syn-
drome is rare among patients with idiopathic hypoparathyroidism, at
least in India. From each patient, 10 ml blood were drawn in 3% EDTA,
and genomic DNA was extracted from blood using the standard phenol-
chloroform extraction technique (17). The institutional ethics committee
of All India Institute of Medical Sciences approved the project, and
written informed consent was obtained from all study subjects. Analysis
of the two SNPs in the PTH gene using DraII and BstBI restriction
endonucleases was performed using PCR-restriction fragment length
polymorphism for all 49 patients with idiopathic hypoparathyroidism
as well as 55 healthy controls. Sequencing of the PTH gene was per-
formed in samples from 37 patients and five healthy volunteers.
Forward and reverse primers used to amplify exons 2 and 3 of the
PTH gene were based on the report by Sunthornthepvarakul et al. (3).
Besides amplifying exon 2 and the section of exon 3 that coded for PTH,
these primers also amplified intron 2 and a part of intron 1 flanking the
5 region of exon 1 (3). PAGE-purified oligonucleotide primers, 5-
gcttctcgtgaaacaacatggt-3 (forward) and 5-ccctacactgtctagagcag-3 (re-
verse), were custom-synthesized (Microsynth GmbH, Balgach, Switzer-
land). The conditions for amplification by PCR were as follows: 100 ng
genomic DNA, 100 pmol of each primer, 200 mol/liter of each deoxy-
NTP, 2.5 mmol/liter MgCl2, 5 mmol/liter Tris-HCl (pH 8.0), 10 mmol/
liter NaCl, 10 mol/liter EDTA, 0.5 mmol/liter dithiothreitol, 5% glyc-
erol, 0.1% Triton X-100, and 1.25 U Taq DNA polymerase. The initial
denaturation was performed at 94 C for 5 min, followed by 35 cycles of
94 C for 1 min, 58 C for 2 min, and 72 C for 1 min and a final extension
at 72 C for 7 min. In 40 patients and eight healthy controls, the 3-UTR
region of exon 3 of the PTH gene was amplified using primers designed
based on the published sequence of the PTH gene (4). The forward
primer sequence was 5-cttggagaggcagacaaagc-3, and the reverse
primer sequence was 5-catgtgggtatcagtgataacc-3. The conditions for
PCR for amplification of the 3-UTR region were same as those described
above, but the temperature for annealing was 55 C. Electrophoresis of
the amplified DNA fragments was carried out on 1% agarose gel in
Tris-borate/EDTA electrophoresis buffer and was visualized by
ethidium bromide staining and a UV light illuminator. Serum calcium
and inorganic phosphorus levels were measured using standard tech-
niques (18). iPTH was measured using an immunoradiometric assay
(DiaSorin, Inc., Stillwater, MN; normal range, 13–54 pg/ml; intraassay
coefficient of variation, 4%).
Sequencing of PCR-amplified products
All PCR-amplified samples were purified using an ExoSAP-IT kit
(Amersham Biosciences, Arlington Heights, IL) and were sequenced
using both forward as well as reverse primers. Sequencing reactions
were performed using the Big Dye Terminator Cycle Sequencing version
3.0 Ready Reaction Kit with AmpliTaq polymerase (Applied Biosystems,
Foster City, CA). Each reaction consisted of 1 l reaction mix, 1.5 l
dilution buffer, 1 l (5 pmol) forward or reverse primer, 5 l (150–200
ng) ExoSAP-purified DNA template, and 1.5l sterilized water in a final
reaction volume of 10 l. Sequencing PCR was carried out in an ABI
thermocycler programmed for 25 cycles each at 96 C for 10 sec, 55 C for
5 sec, and 60 C for 2 min, followed by ethanol precipitation; air-dried for
5–10 min; and then dissolved in 10 l Hi-Di formamide (Applied Bio-
systems). Sequencing was performed by running the samples in a fully
automated 96-capillary-based ABI PRISM 3700 DNA sequencer for 4 h
at 6000 V. A change in the base sequence was considered significant only
when it was present in both the sense and antisense strands. BLAST
(www.ncbi.nlm.nih.gov/blast) was used for identity search by compar-
ing the sequence obtained with the published sequence of the PTH gene,
including its 3-UTR region.
Analysis of SNPs in the PTH gene
After amplification, a 40-l aliquot of the PCR product of the PTH
gene was incubated at 37 C with 10 U DraII (Fermantas, Inc., Hannover,
MD) for 3 h. In the case of BstBI, 5 U enzyme were used for 20-l PCR
products. The digested products were electrophoresed on 1.5% agarose
gel to visualize the fragments. The SNP leading to the C3A substitution
at codon 52 (CGA) in exon 3 of the PTH gene results in loss of the
restriction site for the endonuclease DraII. The presence of normal allele
(nucleotide C) at this position produces two fragments of 434 and 175
FIG. 1. A schematic representation of the arrangement of
introns and exons in the PTH gene, which codes for the
prepro-PTH molecule. SP, Signal peptide coding for 25
amino acids; PH, prohormone.
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bp after restriction enzyme digestion (Fig. 2A). The individuals carrying
this allele in homozygous form were designated DD in this study; those
with all the three fragments (609, 434, and 175 bp) were heterozygotes
and were referred to as Dd. The individuals carrying the mutant allele
in the homozygous form as indicated by the presence of a single 609-bp
fragment were designated dd. The SNP leading to the G3A substitution
in intron 2 of the PTH gene resulted in loss of the restriction sites for the
endonuclease BstBI. Normal homozygotes (with 383- and 226-bp frag-
ments), heterozygotes (609-, 383-, and 226-bp fragments) and mutant
homozygotes (609-bp fragment) carrying the SNP for the BstBI enzyme
were referred to as BB, Bb, and bb, respectively (Fig. 2B).
Statistical analysis
Fischer’s exact test was used to study the significance of the difference
observed in the frequency of occurrence of different types of alleles
between the patient and the control groups after DraII and BstBI diges-
tion. The mean age of onset of disease; serum calcium, phosphorus, and
iPTH levels; and frequency of various clinical manifestations were com-
pared in different genotypes using t test and 2 analysis, respectively.
Results
The published sequence of the human PTH gene (4) was
compared with the sequence data obtained from the analysis
of samples from 37 patients and five controls in this study.
The results revealed that there were no changes in the se-
quence of bases in the signal peptide, prohormone-encoding
region of the PTH gene of any of the subjects. However,
analysis of the sequence data of the PTH gene revealed that
in 13 of the 37 patients (35.1%) and in two of the five controls
(40%), there was an A3G substitution in intron 1. In five of
the 37 patients (13.5%) and in one of the five controls (20%),
there was a C3A substitution at codon 52 (CGA) in the exon
3 of the PTH-encoding region. However, codons CGA and
AGA conserve the amino acid arginine at this position in the
PTH molecule. Two of the patients also had a G3A substi-
tution in the intron 2, 54 nucleotides downstream of 3 end
of exon 2 (Fig. 3). The possibility of the G3A substitution
observed in the present study leading to the formation of a
new mammalian branch point consensus sequence (and thus
possibly altered splicing of PTH pre-mRNA) was calculated
using the method described by Shapiro and Senapathy (19,
20) and the slice applet score chart (http://home.snafu.de/
probins/Splice/shapiroSenapathy.html). The maximum score
of any possible new combination of nucleotide sequence
generated due to the G3A substitution (and thus a possible
invariant A and a new branch point consensus sequence) was
only 61% (Fig. 3).
All three single nucleotide changes described above are
common and are located at well recognized sites for SNPs in
the PTH gene (10, 21). When two of these three SNPs de-
scribed above [C3A substitution at codon 52 (CGA) in exon
FIG. 3. A part of the sequence for intron 2 showing the G3A sub-
stitution at 54 nucleotides downstream of exon 2. The perfect branch
point consensus nucleotide sequence (rectangular box) with a branch
point score greater than 96% is already located 11 nucleotides down-
stream of the observed G3A substitution.
FIG. 2. A, A 1.5% agarose gel electrophoresis after DraII restriction enzyme digestion showing 434- and 175-bp fragments of the PTH gene (lanes
2–18). Lanes 3, 4, 8, 12, 13, and 17 are samples from normal homozygotes (DD). Lanes 2, 5–7, 9–11, and 14–16 are from heterozygotes (Dd),
and lane 18 is the homozygote with the SNP (dd). Lanes 1 and 19 contain a 100-bp DNA ladder. B, A 1.5% agarose gel electrophoresis after
BstBI restriction enzyme digestion of the PTH gene showing 383- and 226-bp fragments of the PTH gene (lanes 2–29). Lanes 3, 16, 18, 22, and
26 contain samples from heterozygotes with SNP designated Bb. Other lanes belong to the normal homozygotes with SNP (BB). A 100-bp DNA
ladder was run in lanes 1 and 30.
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3 and G3A substitution in intron 2] were further studied
with restriction analysis using DraII and BstBI, respectively,
there were no significant differences in the frequency of
occurrence of various genotypes between the patient and
control groups [patient vs. control groups: DD, 44.3% vs.
41.8% (P  0.48); Dd, 46.1% vs. 49.1% (P  0.45); dd, 9.6%
vs. 9.1% (P  0.59); BB, 73.0% vs. 74.4% (P  0.51); Bb, 25.0%
vs. 16.5% (P  0.28); bb, 2.0% vs. 9.1% (P  0.12%; Fig. 2].
To study the relationship between various PTH gene poly-
morphisms and clinical manifestations of the disease in id-
iopathic hypoparathyroidism, the patients were divided into
groups based on the presence or absence of SNPs at the BstBI
and DraII restriction sites. After restriction digestion with
BstBI, the number of patients bearing either the Bb allele or
bb allele was few, and these subjects were therefore analyzed
as a single group and compared with those having the BB
genotype. For the same reasons, patients bearing the Dd and
dd alleles were also grouped together and compared with
those having the DD homozygote. Examination of the results
showed that there was no significant difference between
patients with and without the two PTH gene SNPs studied
with regard to the mean age at onset of symptoms, body mass
index, frequency of occurrence of cataract, tetany, convul-
sion, basal ganglia calcification, serum calcium, inorganic
phosphorus, and levels of intact PTH (Table 1).
In the present study using the primers we designed to
amplify 3-UTR of the PTH gene, PCR yielded the expected
product of 433 bp. Comparison of its sequence data with the
published sequence (4) of the 3-UTR of the human PTH gene
did not reveal any variation in the nucleotide sequences of
the 40 patients and eight controls studied.
Discussion
The pathogenesis of the sporadic form of idiopathic hy-
poparathyroidism is an issue presently under investigation.
In a patient belonging to a family with autosomal dominant
hypoparathyroidism, Arnold et al. (2) detected a T3C mu-
tation in exon 2 of the PTH gene, which resulted in a cysteine
to arginine substitution at position 18 of the 31-amino acid,
prepro sequence of PTH. Suprasdngsin et al. (8) reported
same mutation (T3C) in an isolated patient with sporadic
idiopathic hypoparathyroidism. Parkinson and Thakker (7)
studied three siblings with isolated hypoparathyroidism
(two females and a male) whose parents were first cousins.
They found that the affected individuals were homozygous
for a mutation of the PTH gene that substituted C3G at the
first nucleotide of intron 2 of the PTH gene. This mutation
resulted in exon skipping and resultant loss of exon 2, which
encoded the signal peptide, leading to PTH deficiency (7). In
view of these reports of mutations in the PTH gene in the
familial as well as sporadic forms of hypoparathyroidism (2,
3, 7, 8), we investigated a group of patients with sporadic
idiopathic hypoparathyroidism and examined samples from
them for the occurrence of similar mutations.
Although we did not find any mutations in the region
coding for the signal peptide or the PTH gene in any of the
patients, SNPs occurred frequently at three sites in both
patients and controls. A similarly high frequency of occur-
rence of nucleotide substitution described above was re-
ported earlier by Miric and Levine (21) in patients with
familial isolated hypoparathyroidism as well as in a cohort
of unrelated Caucasian individuals who had no known his-
tory of PTH deficiency.
Interestingly, in the present study 27% of the patients
studied also had a G3A substitution in intron 2 at 54 nu-
cleotides downstream of the 3 end of exon 2 (or 50 nucle-
otides upstream of the 3 splice acceptor site). In the process
of splicing, a short conserved sequence, termed a branch
point consensus nucleotide sequence, functions as the rec-
ognition signal for the spliceosome, which then excises the
intron in the form of a lariat (19, 20). The branch point
consensus nucleotide sequence is characterized by a highly
conserved adenosine residue, which serves as an anchor for
the formation of the spliceosome and is located between 10
and 50 nucleotides upstream of the 3 splice site. The G3A
substitution observed in the patients in this study can the-
oretically result in a new combination of nucleotide se-
quences, which may hypothetically produce another invari-
ant adenosine residue and create a different branch point
consensus nucleotide sequence. Shapiro, Senapathy and
Harris (19, 22) studied the branch point nucleotide sequences
of several genes and devised a scoring system for predicting
the probability of a potential branch point existing in a spe-
cific nucleotide sequence. Using this method a sequence that
scores higher than 96%, would indicate a branch point and
corresponds to only four possible nucleotide sequences, i.e.
CTGAC, CTAAC, CTGAT, and CTAAT. A recent report has
shown the presence of a mutation in the branch point con-
TABLE 1. Clinical and biochemical indexes of patients with idiopathic hypoparathyroidism in relation to the occurrence of SNP in the
PTH gene recognized by DraII and BstBI restriction enzymes
Parameters
Genotype characterized by DraII enzyme
P value
Genotype characterized by BstBI enzyme
P value
DD (n  21) Dd or dd (n  28) BB (n  36) Bb or bb (n  13)
Males:females (no.) 10:11 17:11 19:17 8:5
BMI (kg/m2) 21.7  4.1 20.9  5.5 0.59 20.7  4.6 22.6  5.4
Age of onset of symptoms (yr) 23.2  14.1 26.8  12.6 0.35 27.0  12.8 20.4  13.9 0.12
Convulsions [no. (%)] 14/21 (66.6) 17/28 (60.7) 0.89 21/36 (58.3) 10/13 (76.9) 0.73
Cataract [no. (%)] 7/20 (35.0) 11/28 (39.2) 0.76 14/35 (40.0) 4/13 (30.7) 0.25
Basal ganglia calcification [no. (%)] 15/20 (75.0) 21/27 (77.7) 0.82 26/34 (76.4) 10/13 (76.9) 0.81
Serum total calcium (mg/dl) 6.09  0.77 5.68  1.18 0.29 6.13  0.98 5.60  1.10 0.20
Serum inorganic phosphorus (mg/dl) 6.39  1.14 6.27  1.44 0.64 6.27  1.35 6.57  1.23 0.49
iPTH (pg/ml) 8.8  5.3 11.7  10.7 0.23 8.3  4.0 11.2  10.0 0.15
Results are expressed as mean  SD. (Normal range for serum total calcium, 9.0–11.5 mg/dl; inorganic phosphorus, 2.5–4.5 mg/dl; and for
iPTH, 13–54 pg/ml). SI conversion for serum total calcium is 0.2495 mmol/liter; for inorganic phosphorus 0.3229 mmol/liter.
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sensus nucleotide sequence to be associated with familial
hypercholesteremia (23). In view of this using the method
described by Shapiro and Senapathy (20), we examined the
data from the present study to determine whether the G3A
substitution observed in intron 2 could have led to the for-
mation of a new mammalian branch point consensus nucle-
otide sequence and consequent altered splicing of the PTH-
pre-mRNA. The results of the analysis showed that this
possibility was unlikely because a perfect branch point con-
sensus sequence (CTAAT) with a score greater than 96%
already existed at 30 nucleotides upstream of the 3 acceptor
site of exon 3 located in intron 2 (Fig. 3). Any other new
combination of nucleotide sequences generated by the G3A
substitution observed in this study had a maximum score of
only 61% for possibly creating a new branch point consensus
sequence and therefore would not affect the splicing of the
pre-mRNA. In fact, in several Western and Japanese popu-
lations, the G3A substitution in intron 2 is a frequently
reported polymorphism (10–11).
The C3A substitution at codon 52 (CGA) in exon 3 and
the G3A substitution in intron 2 lead to disruption of re-
striction sites BstBI and DraII. Using these restriction en-
zymes several studies recently reported a correlation be-
tween the presence of the above SNPs and the occurrence of
osteoporosis. Recently, Kanzawa et al. (12) reported higher
circulating levels of iPTH and alkaline phosphatase in pa-
tients with primary hyperparathyroidism belonging to the
BBDD genotype. However, in the present study there was no
significant association between the various clinical mani-
festations or biochemical indexes of the disease and the
presence of these SNPs either in isolation or in various
combinations in patients with sporadic idiopathic hypopar-
athyroidism. This further demonstrated that in the group of
patients we studied, the SNPs observed in the PTH gene were
silent polymorphisms and were not linked to hypoparathy-
roidism or any of its clinical manifestations, such as basal
ganglia calcification, cataract, and convulsions in them.
The terminal nucleotides of the 3-UTR of the PTH gene are
related to the stability of the PTH mRNA transcript and
protect the inherently unstable 3-UTR section by binding to
certain parathyroid-specific cytosolic proteins at a highly
conserved 26-nucleotide sequence located in the distal ter-
minal section of the 3-UTR (6). In in vitro experiments carried
out to assess the stability of PTH mRNA, Moallem et al. (24,
25) observed an increased stability of PTH mRNA probes
without the 3-UTR compared with that of probes with intact
3-UTR. Prolonged hypocalcemia enhanced the stability, and
hypophosphatemia led to decreased stability of PTH mRNA
transcripts (24, 25). Because hypoparathyroidism is charac-
terized by severe hypocalcemia with coexisting hyperphos-
phatemia, it could theoretically be associated with either an
unchanged or an enhanced stability of the PTH mRNA tran-
script. Correspondingly in the present study we did not
observe any change in the sequence of this 3-UTR of the PTH
gene, including the conserved stretch of 26 nucleotides. The
presence of a normal 3-UTR sequence in association with
severe hypocalcemia and hyperphosphatemia should, in the-
ory at least, lead to enhanced stability of the PTH mRNA
transcript, rather than decreased stability; this rules out the
role of mRNA instability in the pathogenesis of idiopathic
hypoparathyroidism.
There are reports of patients with familial as well as spo-
radic forms of hypoparathyroidism and of mutations trig-
gering constitutive activation of the CaSR (26, 27). Ding et al.
(28) reported a patient with familial isolated hypoparathy-
roidism with a mutation in the gene coding for the recently
discovered parathyroid cell-specific transcription factor
GCMb, which belongs to the family of glial cell missing
transcription factors. Transcription factors have also been
reported to function as autoantigens in type 1 diabetes, sys-
temic sclerosis, and lymphocytic hypophysitis, which are
diseases well recognized to have an autoimmune basis (29–
31). To understand the etiology of the various types of spo-
radic idiopathic hypoparathyroidism, additional investiga-
tions must be carried out to detect any modifications in the
normal sequence of various candidate genes and to examine
the concept of a parathyroid-specific transcription factor
functioning as a potential autoantigen.
Hence, the findings of the present study suggest that the
sporadic form of idiopathic hypoparathyroidism does not
originate from mutations in either the PTH gene or in its
3-UTR. The commonly described polymorphisms in the
PTH gene did not segregate the patients with respect to the
clinical manifestations of the disease. Although the present
work did not contribute any new information regarding the
mechanisms underlying the pathogenesis of idiopathic hy-
poparathyroidism, it adds positive information that muta-
tions in the PTH gene or its SNPs are not an important cause
of the sporadic form of idiopathic hypoparathyroidism. Ad-
ditional studies are required to determine the involvement of
other candidate genes and new autoantigens, other than the
CaSR, in the pathogenesis of idiopathic hypoparathyroidism.
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